Results 131 to 140 of about 28,421 (276)

A Dynamical Analysis on a Tumour Virotherapy Model with Standard Incident Rate [PDF]

, 2017
This paper discusses a dynamical analysis on a model that governs the growth of tumour cell under a therapy by using oncolytic viruses, on the standard incident rate.
Ikawati, D. S. (Deasy), Kusumawinahyu, W. M. (Wuryansari), Trisilowati, T. (Trisilowati)   +2 more
core  

Strategies in Gene Therapy for Glioblastoma [PDF]

, 2013
Glioblastoma (GBM) is the most aggressive form of brain cancer, with a dismal prognosis and extremely low percentage of survivors. Novel therapies are in dire need to improve the clinical management of these tumors and extend patient survival.
Behera, Prajna, Chiocca, E. Antonio, Kwiatkowska, Aneta, Nandhu, Mohan S., Viapiano, Mariano S.   +4 more
core   +2 more sources

Peritoneal Immunosurgery: Immunotherapy Augmented Surgery for the Treatment of Peritoneal Cancers

Journal of Surgical Oncology, Volume 132, Issue 5, Page 789-809, October 2025.
ABSTRACT Peritoneal malignancy often indicates disruptions in multiple physiological systems resulting from widespread cancer. The heterogenous origin and dynamic nature of peritoneal cancer make it difficult to treat with standard approaches that fit into guidelines.
Ada I. Ozcan, Arianexys Aquino López, Mary K. McKenna, Malcolm K. Brenner, Alastair M. Thompson   +4 more
wiley   +1 more source

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment

Frontiers in Immunology, 2018
Adoptive T-cell immunotherapies, including chimeric antigen receptor-modified T-cells (CAR-T cells), have revolutionized cancer treatment, especially for hematologic malignancies.
Amanda Rosewell Shaw, Amanda Rosewell Shaw, Masataka Suzuki, Masataka Suzuki   +3 more
doaj   +1 more source

Virotheranostics, a double-barreled viral gun pointed toward cancer; ready to shoot?

Cancer Cell International, 2020
Compared with conventional cancer treatments, the main advantage of oncolytic virotherapy is its tumor-selective replication followed by the destruction of malignant cells without damaging healthy cells.
Mohsen Keshavarz, Ailar Sabbaghi, Seyed Mohammad Miri, Abolhasan Rezaeyan, Yaser Arjeini, Amir Ghaemi   +5 more
doaj   +1 more source

Promising Cancer Vaccine for Glioblastoma Therapy: A Focus on mRNA Vaccine

Cancer Medicine, Volume 14, Issue 18, September 2025.
ABSTRACT Background Glioblastoma (GBM) is an aggressive primary brain tumor with poor prognosis and low survival rates. Standard treatments, such as surgery and radiotherapy, are limited by tumor infiltration and resistance. To review current vaccine strategies for GBM, including peptide, virotherapy, cell‐based, and genetic vaccines, with a focus on ...
Sama Barati, Sahar Ghoflchi, Pejman Hosseinzadeh, Sobhan Pouramini, Hossein Hosseini, Mohammad Jalili‐Nik   +5 more
wiley   +1 more source

Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment

Molecular Therapy: Oncolytics, 2018
Ewing sarcoma is a highly aggressive cancer that promotes the infiltration and activation of pro-tumor M2-like macrophages. Oncolytic virotherapy that selectively infects and destroys cancer cells is a promising option for treating Ewing sarcoma.
Nicholas L. Denton, Chun-Yu Chen, Brian Hutzen, Mark A. Currier, Thomas Scott, Brooke Nartker, Jennifer L. Leddon, Pin-Yi Wang, Rachelle Srinivas, Kevin A. Cassady, William F. Goins, Timothy P. Cripe   +11 more
doaj   +1 more source

Oncolytic Viroradiotherapy for Neuroblastoma [PDF]

, 2014
College of Education and Human Ecology Undergraduate Research ScholarshipNeuroblastoma is the most common extra-cranial solid tumor in childhood and the leading cause of childhood cancer mortality.
Kunkler, Anne
core  

The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma [PDF]

, 2015
Anaplastic thyroid carcinoma (ATC) is one of the most aggressive human solid tumor and current treatments are ineffective in increasing patients' survival. Thus, the development of new therapeutic approaches for ATC is needed.
Ayyoub, Baeuerle, Bell, Bell, Bell, Benveniste, Bonecchi, Burgert, Chariot, Chieffi, Cobb, Coussens, Curti, Di Cristofano, Dupuy, Fagin, Fernando, Feuerer, Fidler, Fong, Fueyo, Ghosh, Giordano, Guo, Hallden, Hallden, Hanahan, Haugen, Haugen, Hickman, Horwitz, Horwitz, Iwasaki, Kairemo, Karin, Kirn, Kirn, Kracht, Leonardi, Maeda, Mameli, Mantovani, Mantovani, Mantovani, Matsuno, McCart, McKiernan, Melcher, Melillo, Nemunaitis, Okubo, Pinchera, Pollard, Portella, Portella, Portella, Portella, Portella, Portella, Portella, Rabkin, Remick, Ribatti, Rice, Schmittgen, Sheridan, Syed, Tanaka, Udelsman, Vilcek, Weinberg, Wilson   +71 more
core   +2 more sources

Two Decades of Optogenetic Tools: A Retrospective and a Look Ahead

Advanced Genetics, Volume 6, Issue 3, September 2025.
Optogenetics provides up to millisecond scale, cell type‐specific control of biology using light‐sensitive proteins. This review chronicles two decades of tool development, from microbial rhodopsins and photoactivated enzymes to allosteric switches, surveys broad applications in neuroscience, molecular and cell biology, cardiology, immunology, and ...
Xiao Duan, Mo Zhu, Shiqiang Gao
wiley   +1 more source